Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
LNP023 - Factor B inhibition of the complement alternative
pathway
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03373461 (CLNP023X2203)
IgA nephropathy (IgAN)
Phase 2
112
Change from baseline of log transformed UPCR derived from the 24h urine
collections at Baseline and Day 90
Placebo
LNP023 Dose 1
LNP023 Dose 2
LNP023 Dose 3
LNP023 Dose 4
NCT03439839 (CLNP023X2201)
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2
16
Reduction of chronic hemolysis, based on LDH level at Week 13
10 patients receiving LNP023 high dose daily over up to approximately 3 years
5 patients receiving LNP023 low dose daily over up to approximately 3 years
Target Patients
Read-out Milesstone(s)
Publication
Patients with biopsy-verified IgA nephropathy
H1-2021 (actual)
Barratt et al. 2021. Oral Presentation at the 58th ERA-EDTA congress (Late
Breaking Clinical Trials), June 6: IA2 results.
Patients with PNH, showing signs of active hemolysis despite treatment with SoC
(defined as an antibody with anti C5 activity).
Primary: Q2-2020 (actual)
Extension: 2023
Antonio M. Risitano, MD, PhD1 et al. Presented at EBMT 2020 congress
Jan 2021Pubs: Lancet Haematol - Study of Safety, Efficacy, Tolerability,
Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With
Paroxysmal Nocturnal Hemoglobinuria (PNH)
64 Investor Relations | Q2 2021 Results
ā NOVARTIS | Reimagining MedicineView entire presentation